Genentech and Lonza announce Manufacturing Agreement

16-Dec-2003

Genentech, Inc. and Lonza Group Ltd announced that the companies have entered into a long-term manufacturing agreement under which Lonza Biologics will manufacture commercial quantities of Rituxan® (Rituximab) for Genentech at its production facility in Portsmouth, New Hampshire. Financial terms of the agreement have not been disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!